GoodRx (NASDAQ:GDRX) Sets New 1-Year Low – What’s Next?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $2.61 and last traded at $2.6250, with a volume of 784068 shares changing hands. The stock had previously closed at $2.68.

Wall Street Analysts Forecast Growth

GDRX has been the subject of a number of recent analyst reports. Morgan Stanley decreased their price target on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Weiss Ratings reissued a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. Citigroup lowered their target price on GoodRx from $5.00 to $4.50 and set a “buy” rating on the stock in a report on Friday, January 9th. JPMorgan Chase & Co. cut their price target on GoodRx from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.91.

GoodRx Stock Performance

The firm has a fifty day simple moving average of $2.78 and a 200 day simple moving average of $3.72. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock has a market cap of $882.52 million, a price-to-earnings ratio of 28.89, a PEG ratio of 1.02 and a beta of 1.45.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business’s revenue for the quarter was up .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.08 earnings per share. As a group, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Institutional Trading of GoodRx

Institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC raised its position in GoodRx by 124.4% in the first quarter. AQR Capital Management LLC now owns 282,320 shares of the company’s stock worth $1,245,000 after purchasing an additional 156,482 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of GoodRx by 7.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock valued at $3,455,000 after purchasing an additional 54,783 shares during the period. Jane Street Group LLC acquired a new position in shares of GoodRx in the 1st quarter worth approximately $370,000. Counterpoint Mutual Funds LLC bought a new position in shares of GoodRx during the 2nd quarter worth approximately $382,000. Finally, Ballentine Partners LLC bought a new position in shares of GoodRx during the 2nd quarter worth approximately $121,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.